Symphogen A/S
Latest round
- Series E
Last raised
- Jan 2007
Total raised
- $57M
Investors
- 7
About Symphogen A/S
Founded in 2000, Symphogen A/S specializes in the development of antibody therapies targeting cancer. The company has undergone various strategic pivots over the years, enhancing its focus on oncology. As of now, it operates its headquarters in Denmark and has undertaken a total of 11 deals.00 mn.Symphogen specializes in developing innovative antibody therapies primarily for oncology and immune oncology. The company has established a robust antibody discovery and research platform that enables the creation of unique antibodies, aimed at addressing complex tumor environments and improving patient outcomes.10. The company generates revenue through partnerships with pharmaceutical companies, engaging in collaborative agreements to co-develop therapies and share the risks and rewards of the development process.Symphogen A/S is poised for future growth through the development of new antibody products and a strategic focus on expanding into additional markets. The company plans to target regions in Asia and North America for market expansion by 2025. Additionally, EW Healthcare Partners has acquired Symphogen A/S, further positioning the company for growth and innovation.
Who invested in Symphogen A/S
7 investors across 3 rounds
See all investors in Symphogen A/S
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Symphogen A/S
Who invested in Symphogen A/S?
Symphogen A/S has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Symphogen A/S raised?
Symphogen A/S has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Symphogen A/S last raise money?
Symphogen A/S's most recent round on record is a Series E, in Jan 2007.
What does Symphogen A/S do?
Founded in 2000, Symphogen A/S specializes in the development of antibody therapies targeting cancer.
Where is Symphogen A/S headquartered?
Symphogen A/S is headquartered in Denmark.
Which VCs invest in companies like Symphogen A/S?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Symphogen A/S's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Symphogen A/S? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.